InflaRx’s lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase 3 clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. It is in a Phase 2 trial for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease; a Phase 2a exploratory study to treat pyoderma gangraenosum, a chronic inflammatory skin disorder; and in Phase 2 for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma.
The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology and clinical trial collaboration and supply agreement with Merck.
Raymond James has an $8.12 price target. The consensus target is $5.50, and shares traded on Friday at $2.50. Hitting the Raymond James target would be a 232% gain.
Ocular Therapeutics
This micro-cap biopharmaceutical company could really be a big winner with an aging population. Ocular Therapeutics Inc. (NASDAQ: OCUL) focuses on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery. Its Dextenza is a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet ageelated macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant that is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
The company has a strategic collaboration with Regeneron Pharmaceuticals for the development and commercialization of products using the company’s sustainedelease hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases. It has a strategic collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC. And it has a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry ageelated macular degeneration (dMAD).
The $14 Raymond James target price compares with a $13.29 consensus target. The stock traded on Friday at $3.00. A move to the target would be a 370% gain.
24/7 TempoSponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
